Stockreport

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

Albireo Pharma, Inc.  (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
PDF – Initiation of Phase 2 clinical trial expected in Q2 2019 – – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) - [Read more]